Live Breaking News & Updates on Yaron Pereg|Page 3

Stay updated with breaking news from Yaron pereg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers

KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR's Lead Anti-CD47 Candidate in Blood Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Israel General , United States , Tsipi Haitovsky , Barbara Lindheim , Ross Barrett , Clayton Boldt , Yaron Pereg , Jalan Lada , Cancer Focus Fund , University Of Texas Md Anderson Cancer Center , Hadassit Bio Holdings , Feist Weiller Cancer Center Shreveport , Oriella Limiteda Consensus Business Group , Department Of Leukemia , Partner Of Cancer Focus Fund , Md Anderson Institutional Conflict Of Interest Committee , Cancer Focus Fundthe Fund , Cancer Center , Focus Fund , Managing Partner , Cancer Focus , Naval Daver , Associate Professor , Flerie Invest , Oriella Limited , Consensus Business Group Limited ,

Immuno-oncology startup KAHR to work with Philadelphia university on new drugs

Illustrative image of cancer cells (Design Cells; iStock by Getty Images)
KAHR, a maker of cancer immunotherapies, said it has entered into an exclusive licensing agreement with Thomas Jefferson University in Philadelphia to develop and commercialize a number of new cancer drug candidates.
Under the agreement, the university is granting KAHR the license to develop and commercialize new immuno-oncology drug candidates based on fusion proteins. These drugs are complex structures made by fusing the natural sequence of different proteins to make them bind two or three targets on cancer and immune cells. The new drug candidates entering development are called DSP502 (TIGITxPD1) and DSP216 (LILRB2xSIRPa). ....

Thomas Jefferson University , United States , Mark Tykocinski , Yaron Pereg , Hadasit Bio , Sidney Kimmel Medical College , Drug Administration , Sidney Kimmel Medical , Flerie Invest , Oriella Limited , Hadasit Bio Holdings , Pavilion Capital , Mirae Asset Venture Investment , Korean Investment Partners , தாமஸ் ஜெஃபர்சன் பல்கலைக்கழகம் , ஒன்றுபட்டது மாநிலங்களில் , சிட்னி கீம்மேல் மருத்துவ கல்லூரி , சிட்னி கீம்மேல் மருத்துவ , பெவிலியன் மூலதனம் , மீரே சொத்து துணிகர முதலீடு , கொரியன் முதலீடு கூட்டாளர்கள் ,

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy

Share this article
Share this article
JERUSALEM, April 1, 2021 /PRNewswire/ KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, announced today that it has entered into a licensing agreement with Thomas Jefferson University a national doctoral research university and its clinical enterprise, Jefferson Health, located in Philadelphia, PA. Under the agreement, Thomas Jefferson University is granting KAHR an exclusive license to develop and commercialize multiple new drug candidates including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein for immuno-oncology.
With this agreement we are adding a second fusion protein platform to our portfolio, enabling us to broaden our immuno-oncology target pipeline and positioning KAHR as a world leader in the fusion protein space, said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. Both DSP502 and DSP216 focus on promising checkpoint pathways ....

United States , Israel General , Thomas Jefferson University , Tsipi Haitovsky , Bryan Jennings , Thomas Hoffmann , Rose Ritts , Heather Rose , Mark Tykocinski , Yaron Pereg , Edyta Zielinska , Kanbar College Of Design , Provost Of Thomas Jefferson University , Hadassit Bio Holdings , Oriella Limiteda Consensus Business Group , Sidney Kimmel Medical College , Jefferson Health , Science Communications , Division Ii Central Atlantic Collegiate Conference , Thomas Jefferson , Chief Executive Officer , Sidney Kimmel Medical , Innovation Vice President , Innovation Executive Vice President , Flerie Invest , Oriella Limited ,